New Zealand markets closed

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
171.43-2.47 (-1.42%)
At close: 4:00PM EDT
170.20 -1.23 (-0.72%)
After hours: 05:34PM EDT

Seagen Inc.

21823 30th Drive SE
Bothell, WA 98021
United States
425 527 4000
http://www.seagen.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees2,092

Key executives

NameTitlePayExercisedYear born
Dr. Clay B. SiegallCo-Founder, Chairman, Pres & CEO2.64M39.53M1961
Mr. Todd E. SimpsonChief Financial Officer620.67k13.7M1961
Ms. Jean I. Liu J.D., M.S.Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.963.45k2.46M1968
Mr. Charles R. RompExec. VP of Commercial U.S.829.16k6.66M1968
Dr. Roger D. Dansey M.D.Chief Medical Officer1.65M1.17M1957
Dr. Vaughn B. HimesChief Technical OfficerN/AN/A1961
Peggy PinkstonVP of Investor RelationsN/AN/AN/A
Ms. Natasha A. HerndayExec. VP of Corp. Devel.N/AN/A1972
Mr. Matt SkeltonVP of MarketingN/AN/AN/A
Mr. Christopher P. PawlowiczExec. VP of HRN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Corporate governance

Seagen Inc.’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 5; Board: 4; Shareholder rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.